Involvement of sialoglycans in SARS-COV-2 infection: Opportunities and challenges for glyco-based inhibitors
Issued Date
2022-12-01
Resource Type
ISSN
15216543
eISSN
15216551
DOI
Scopus ID
2-s2.0-85142246473
Pubmed ID
36349722
Journal Title
IUBMB Life
Volume
74
Issue
12
Start Page
1253
End Page
1263
Rights Holder(s)
SCOPUS
Bibliographic Citation
IUBMB Life Vol.74 No.12 (2022) , 1253-1263
Suggested Citation
Kuhaudomlarp S., Imberty A. Involvement of sialoglycans in SARS-COV-2 infection: Opportunities and challenges for glyco-based inhibitors. IUBMB Life Vol.74 No.12 (2022) , 1253-1263. 1263. doi:10.1002/iub.2692 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87113
Title
Involvement of sialoglycans in SARS-COV-2 infection: Opportunities and challenges for glyco-based inhibitors
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Viral infections have been the causes of global pandemics, including the ongoing coronavirus disease 2019, which prompted the investigation into the infection mechanisms to find treatment and aid the vaccine design. Betacoronaviruses use spike glycoprotein on their surface to bind to host receptors, aiding their host attachment and cell fusion. Protein-glycan interaction has been implicated in the viral entry mechanism of many viruses and has recently been shown in SARS-CoV-2. Here, we reviewed the current knowledge on protein-glycan interactions that facilitate SARS-CoV-2 host entry, with special interest in sialoglycans present on both the virions and host cell surfaces. We also analyze how such information provides opportunities and challenges in glyco-based inhibitors.